What is the recommended management for symptomatic candiduria?

Management of Symptomatic Candiduria

For symptomatic candiduria, treat with oral fluconazole 200 mg (3 mg/kg) daily for 2 weeks for cystitis or 200-400 mg (3-6 mg/kg) daily for 2 weeks for pyelonephritis, and always remove indwelling bladder catheters when feasible. 1

Initial Assessment and Risk Stratification

When candiduria is identified, first determine if the patient is truly symptomatic versus colonized. Symptomatic candiduria presents with:

• Cystitis: Dysuria, urgency, frequency, suprapubic pain
• Pyelonephritis: Fever, flank pain, costovertebral angle tenderness

The critical distinction is that asymptomatic candiduria does not require treatment in most patients, as it typically represents colonization rather than infection 1. However, high-risk patients (neutropenic, very low-birth-weight infants <1500g, or those undergoing urologic procedures) require treatment even when asymptomatic 1.

Treatment Algorithm by Clinical Presentation

For Symptomatic Candida Cystitis:

First-line therapy (fluconazole-susceptible organisms):

• Oral fluconazole 200 mg (3 mg/kg) daily for 2 weeks 1
• Remove indwelling bladder catheter if present (strongly recommended) 1

For fluconazole-resistant C. glabrata:

• Amphotericin B deoxycholate 0.3-0.6 mg/kg daily for 1-7 days, OR
• Oral flucytosine 25 mg/kg four times daily for 7-10 days 1
• Consider amphotericin B bladder irrigation (50 mg/L sterile water daily for 5 days) as adjunctive therapy 1

For C. krusei:

• Amphotericin B deoxycholate 0.3-0.6 mg/kg daily for 1-7 days 1

For Symptomatic Candida Pyelonephritis:

First-line therapy (fluconazole-susceptible organisms):

• Oral fluconazole 200-400 mg (3-6 mg/kg) daily for 2 weeks 1
• Eliminate urinary tract obstruction (strongly recommended) 1
• Remove or replace nephrostomy tubes/stents if feasible 1

For fluconazole-resistant C. glabrata:

• Amphotericin B deoxycholate 0.3-0.6 mg/kg daily for 1-7 days with or without oral flucytosine 25 mg/kg four times daily 1
• Alternative: Flucytosine monotherapy 25 mg/kg four times daily for 2 weeks (weaker recommendation) 1

For C. krusei:

• Amphotericin B deoxycholate 0.3-0.6 mg/kg daily for 1-7 days 1

For Fungal Balls/Bezoars:

• Surgical intervention is strongly recommended 1
• Antifungal treatment as above for cystitis or pyelonephritis 1
• Irrigation through nephrostomy tubes with amphotericin B deoxycholate 25-50 mg in 200-500 mL sterile water 1

Critical Management Principles

Catheter Management:

Removal of indwelling bladder catheters is the single most important intervention and resolves candiduria in approximately 50% of cases without antifungal therapy 2, 3. This should be done as early as possible when feasible 1.

Species-Specific Considerations:

The choice of antifungal depends heavily on the Candida species and local susceptibility patterns:

• C. albicans: Usually fluconazole-susceptible
• C. glabrata: Often fluconazole-resistant, requiring amphotericin B or flucytosine
• C. krusei: Intrinsically fluconazole-resistant, requires amphotericin B

Drug Selection Rationale:

Fluconazole is the preferred agent because it achieves excellent urinary concentrations with oral administration 2, 3. Echinocandins and azoles other than fluconazole are poorly excreted in urine and should not be used for urinary tract candidiasis 2, 3. This is a common pitfall—avoid using micafungin, caspofungin, or anidulafungin for isolated candiduria.

Special Populations

Patients undergoing urologic procedures:

• Treat with oral fluconazole 400 mg (6 mg/kg) daily OR amphotericin B deoxycholate 0.3-0.6 mg/kg daily for several days before and after the procedure 1

Neutropenic patients and very low-birth-weight infants:

• Treat as candidemia (systemic therapy) even if asymptomatic 1

Common Pitfalls to Avoid

1. Overtreating asymptomatic candiduria: Studies show 23-31% of patients receive unnecessary antifungal therapy 4, 5. This increases risk of multidrug-resistant organism colonization without clinical benefit 6.

2. Using echinocandins for urinary candidiasis: These agents do not achieve adequate urinary concentrations 2, 3.

3. Failing to address underlying risk factors: Simply treating with antifungals without removing catheters, stopping antibiotics, or correcting obstruction leads to treatment failure 2, 7.

4. Treating based on single urine culture: Confirm infection with a second sterile urine sample to exclude contamination 8, 7.

5. Assuming candiduria equals candidemia: Candiduria rarely indicates disseminated infection in immunocompetent patients 7, 9.